Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Mepilex Up dressing 20cm x 21cm
20033000521
|
Mepilex Up dressing 20cm x 21cm | Wound Management & Other Dressings | Dressings | No data available |
|
Mepitel dressing 10cm x 18cm
20030900012
|
Mepitel dressing 10cm x 18cm | Wound Management & Other Dressings | Dressings | No data available |
|
Mepitel dressing 20cm x 30cm
20030900013
|
Mepitel dressing 20cm x 30cm | Wound Management & Other Dressings | Dressings | No data available |
|
Mepitel dressing 5cm x 7.5cm
20030900010
|
Mepitel dressing 5cm x 7.5cm | Wound Management & Other Dressings | Dressings | No data available |
|
Mepitel dressing 7.5cm x 10cm
20030900011
|
Mepitel dressing 7.5cm x 10cm | Wound Management & Other Dressings | Dressings | No data available |
|
Mepolizumab 100mg powder for solution for injection vials
0304020Y0AAAAAA
|
Mepolizumab | Mepolizumab | Respiratory System | No data available |
|
Mepolizumab 100mg/1ml inj pre-filled disposable devices
0304020Y0AAACAC
|
Mepolizumab | Mepolizumab | Respiratory System | No data available |
|
Mepolizumab 100mg/1ml inj pre-filled syringes
0304020Y0AAABAB
|
Mepolizumab | Mepolizumab | Respiratory System | No data available |
|
Mepore Ultra dressing 6cm x 7cm
20030100255
|
Mepore Ultra dressing 6cm x 7cm | Wound Management & Other Dressings | Dressings | No data available |
|
Mepore Ultra dressing 9cm x 10cm
20030100256
|
Mepore Ultra dressing 9cm x 10cm | Wound Management & Other Dressings | Dressings | No data available |
|
Mepore Ultra dressing 9cm x 15cm
20030100257
|
Mepore Ultra dressing 9cm x 15cm | Wound Management & Other Dressings | Dressings | No data available |
|
Meprobamate 5mg/5ml oral liquid
0401020R0AAAEAE
|
Meprobamate | Meprobamate | Central Nervous System | No data available |
|
Merbentyl 10mg tablets
0102000J0BBAAAB
|
Merbentyl | Dicycloverine hydrochloride | Gastro-Intestinal System | No data available |
|
Merbentyl 10mg/5ml syrup
0102000J0BBABAA
|
Merbentyl | Dicycloverine hydrochloride | Gastro-Intestinal System | No data available |
|
Merbentyl 20 tablets
0102000J0BBAEAC
|
Merbentyl | Dicycloverine hydrochloride | Gastro-Intestinal System | No data available |
|
Mercaptamine 0.11% eye drops
1108010A0AAABAB
|
Mercaptamine hydrochloride (Eye) | Mercaptamine hydrochloride | Eye | No data available |
|
Mercaptamine 75mg gastro-resistant capsules
0908010E0AAADAD
|
Mercaptamine | Mercaptamine | Nutrition and Blood | No data available |
|
Mercaptopurine 12.5mg capsules
0801030L0AAASAS
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 20mg capsules
0801030L0AAARAR
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 25mg/5ml oral suspension
0801030L0AAAHAH
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 30mg capsules
0801030L0AAAMAM
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 45mg/5ml oral suspension
0801030L0AAAKAK
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 50mg/5ml oral suspension
0801030L0AAAFAF
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 5mg/5ml oral suspension
0801030L0AAACAC
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
|
Mercaptopurine 75mg capsules
0801030L0AAAPAP
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.